Subscribe to RSS
Severe Acute Respiratory Syndrome-Coronavirus-2 Antibody Status at the Time of Delivery and the Risk of PreeclampsiaFunding None.
Objective Our objective was to evaluate the association between severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serologic status in immunologically naive patients and the risk of preeclampsia at the time of delivery.
Study Design We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1 to September 30, 2020. We recorded maternal medical and obstetric characteristics and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed, and patients were classified into seropositive groups: immunoglobulin (Ig)G + , IgM + , or both IgG+ and IgM + . Bivariate and multivariable analyses were performed.
Results We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p = 0.183) or with preeclampsia with severe features (p = 0.916) even after adjusting for maternal age >35, BMI ≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with the development of preeclampsia (odds ratio [OR] = 13.40; 95% confidence interval [CI]: 4.98–36.09; p < 0.05) and with preeclampsia with severe features (OR = 5.46; 95% CI: 1.65–18.02; p < 0.05).
Conclusion We found that in an obstetric population, there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia.
Pregnant people with acute COVID-19 are at an increased risk of developing preeclampsia.
Seroconversion during pregnancy was not associated with an increased risk of preeclampsia.
Further study regarding the timing of infection and its association with preeclampsia is necessary.
Poster presented at the SMFM's 42nd Annual Pregnancy Meeting, Society of Maternal Fetal Medicine, Virtual meeting, January 31–February 5, 2022.
Received: 11 April 2022
Accepted: 22 May 2023
Accepted Manuscript online:
25 May 2023
Article published online:
26 June 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
1 Mortality analyses. Johns Hopkins Coronavirus Resource Center. [cited 2022 Feb20]. Available from: https://coronavirus.jhu.edu/data/mortality
- 2 Schwalb A, Seas C. The COVID-19 pandemic in Peru: what went wrong?. Am J Trop Med Hyg 2021; 104 (04) 1176-1178
- 3 Zambrano LD, Ellington S, Strid P. et al; Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status — United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (44) 1641-1647
4 Centro Nacional de Epidemiología, Prevención y Control de Enfermedades. Situación Epidemiológica de la Mortalidad Materna en el Perú. Viceministerio de Salud Pública. Ministerio de Salud. 2021. Accessed June 8, 2023 at: https://www.dge.gob.pe/portal/docs/tools/teleconferencia/2021/SE162021/03.pdf
- 5 Gurol-Urganci I, Jardine JE, Carroll F. et al. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. Am J Obstet Gynecol 2021; 225 (05) 522.e1-522.e11
- 6 Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol 2022; 226 (01) 68-89.e3 [published online ahead of print, 2021 Jul 21]
- 7 Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123 (24) 2856-2869
- 8 Guevara-Ríos E, Espinola-Sánchez M, Carranza-Asmat C. et al. Anticuerpos anti-SARS-COV-2 en gestantes en un hospital nivel III de Perú. Rev. Peru. Ginecol. Obstet. 2020; 66 (03) 00002 Disponible en: Accessed June 08, 2023 at: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S2304-51322020000300002&lng=es DOI: 10.31403/rpgo.v66i2259.
9 Interim guidelines for covid-19 antibody testing [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; [cited 2022Feb19]. Accessed June 08, 2023 at: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html#print
- 10 Sidiq Z, Hanif M, Dwivedi KK, Chopra KK. Benefits and limitations of serological assays in COVID-19 infection. Indian J Tuberc 2020; 67 (4S): S163-S166
- 11 Gestational Hypertension and Preeclampsia. Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol 2020; 135 (06) e237-e260
- 12 Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol 2019; 15 (05) 275-289 [published correction appears in Nat Rev Nephrol. 2019 Jun;15(6):386]
- 13 Sánchez Sixto E. Actualización en la epidemiología de la preeclampsia: update. Rev Peru Ginecol Obstet 2014; 60 (04) 309-320 Disponible en: Accessed June 08, 2023 at: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S2304-51322014000400007&lng=es
- 14 Pacheco-Romero J, Acosta O, Huerta D. et al. Genetic markers for preeclampsia in Peruvian women. Colomb Med (Cali) 2021; 52 (01) e2014437
- 15 La Rosa M, Ludmir J. Manejo de la preeclampsia con elementos de severidad antes de las 34 semanas de gestación: nuevos conceptos. Rev Peru Ginecol Obstet 2014;60(04) Lima oct./dic
- 16 Peche Dávila G. Preeclampsia con criterios de severidad como factor de riesgo para resultados maternoperinatales adversos Hospital Alberto Sabogal Sologuren 2014-2018. [Proyecto de Investigación]. Lima: Universidad de San Martín de Porres, Facultad de Medicina Humana; 2021: 41
- 17 Di Mascio D, Khalil A, Saccone G. et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020; 2 (02) 100107
- 18 Hansen JN, Hine J, Strout TD. COVID-19 and preeclampsia with severe features at 34-weeks gestation. Am J Emerg Med 2020; 39: 252.e3-252.e5 [published online ahead of print, 2020 Jun 25]
- 19 Antoun L, Taweel NE, Ahmed I, Patni S, Honest H. Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: a prospective cohort study. Eur J Obstet Gynecol Reprod Biol 2020; 252: 559-562
- 20 Villar J, Ariff S, Gunier RB. et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID multinational cohort study. JAMA Pediatr 2021; 175 (08) 817-826
- 21 Qu J, Wu C, Li X. et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71 (16) 2255-2258
- 22 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (02) 271-280.e8
- 23 Verma S, Carter EB, Mysorekar IU. SARS-CoV2 and pregnancy: an invisible enemy?. Am J Reprod Immunol 2020; 84 (05) e13308 [published online ahead of print, 2020 Jul 17]
- 24 Egerup P, Fich Olsen L, Christiansen AH. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies at delivery in women, partners, and newborns. Obstet Gynecol 2021; 137 (01) 49-55
- 25 Crovetto F, Crispi F, Llurba E. et al. Impact of SARS-CoV-2 infection on pregnancy outcomes: a population-based study. Clin Infect Dis 2021; 73 (10) 1768-1775 [published online ahead of print, 2021 Feb 8]
- 26 Khalil A, Samara A, Chowdhury T, O'Brien P. Does COVID-19 cause pre-eclampsia?. Ultrasound Obstet Gynecol 2022; 59 (02) 146-152
- 27 Rosenbloom JI, Raghuraman N, Carter EB, Kelly JC. Coronavirus disease 2019 infection and hypertensive disorders of pregnancy. Am J Obstet Gynecol 2021; 224 (06) 623-624
- 28 Meireles P, Amaro J, Pinto da Costa J. et al. Prevalence of SARS-CoV-2 antibodies among workers of the public higher education institutions of Porto, Portugal: a cross-sectional study. Occup Environ Med 2021; 78 (09) 648-653